Workflow
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics, IncDogwood Therapeutics, Inc(US:DWTX) Globenewswire·2025-11-06 13:45
  • Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction - ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechn ...